EDIT Editas Medicine Inc.

Editas Medicine Announces Upcoming Investor Events

Editas Medicine Announces Upcoming Investor Events

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences:

  • 2023 Wells Fargo Healthcare Conference

    Format: Fireside Chat

    Date: Thursday, September 7

    Time: 3:00 p.m. ET

    Location: Boston, MA
  • Morgan Stanley 21st Annual Global Healthcare Conference

    Format: Fireside Chat

    Date: Monday, September 11

    Time: 10:00 a.m. ET

    Location: New York, NY
  • Cantor Global Healthcare Conference 2023

    Format: Fireside Chat

    Date: Tuesday, September 26

    Time: 1:35 p.m. ET

    Location: New York, NY

To access the live webcasts of Editas Medicine’s presentations, please visit the “Investors” section of the Company’s website at . An archived replay will be available for approximately 30 days following each event.

About Editas Medicine

As a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit .



Media and Investor Contact:
Cristi Barnett
(617) 401-0113
EN
30/08/2023

Underlying

EDITEditas Medicine Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Editas Medicine Inc.

 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Tri...

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%. Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloab...

11h / 8m 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHA...

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant EHA EdiTHAL poster...

11h / 9m 1 EN
Free Trial
EDIT Editas Medicine...

Editas Medicine Inc: 1 director

A director at Editas Medicine Inc bought 45,000 shares at 5.642USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

EDIT EDITAS MEDICINE INC.
05/15/24 May 15, 2024 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Tri...

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 20...

May 14, 2024 1 EN
 PRESS RELEASE
Free
EDIT Editas Medicine...

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gen...

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company’s in vivo gene editing medicines pipeline   CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the presentation of preclinical data demonstrating several in viv...

May 10, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch